Taysha Gene Therapies (TSHA) Reiterated at Market Outperform by Citizens

July 2, 2026 4:19 AM

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $11.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found